Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas

Reinhard Dummer; Stefan Eichmüller; Sylke Gellrich; Chalid Assaf; Brigitte Dreno; Meinhard Schiller; Olivier Dereure; Marion Baudard; Martine Bagot; Amir Khammari; Pascal Bleuzen; Vincent Bataille; Anna Derbij; Nicole Wiedemann; Tim Waterboer; Monika Lusky; Bruce Acres; Mirjana Urosevic-Maiwald

doi:10.1038/mt.2010.52

Retour

Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas

Article de revue

Avec comité de lecture

Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas

Reinhard Dummer, Stefan Eichmüller, Sylke Gellrich, Chalid Assaf, Brigitte Dreno, Meinhard Schiller, Olivier Dereure, Marion Baudard, Martine Bagot, Amir Khammari, …

Molecular therapy, Vol.18(6), pp.1244-1247

01/06/2010

DOI: https://doi.org/10.1038/mt.2010.52

PMID: 20372104

Résumé

Original

Cutaneous lymphomas (CLs) are a heterogeneous group of lymphoproliferative disorders that are manageable by immunotherapy. Twenty-one patients were enrolled in a prospective open-label, dose-escalation multicenter study evaluating the effects of repeated TG1042 [adenovirus-interferon (IFN)-γ] intralesional injections in patients with primary CLs, of which 18 were of T-cell and 3 of B-cell type. Repeated intralesional therapy using TG1042 consistently results in local tumor regressions in about half of treated patients and one-third of patients also in regressions in noninjected distant lesions, likely reflecting the systemic immune activation after intralesional therapy. Treatment was well tolerated with few adverse events including injection site reactions, chills, lymphopenia, and fever. Immune monitoring in the peripheral blood demonstrated systemic immune activation and the induction of antibodies against tumor antigens in some patients without clear association with clinical responses. CLs, in particular B-cell lymphomas with high objective response rates, seem to be excellent targets for this type of immunotherapy.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas
Créateurs - sans rôle: Reinhard Dummer - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Stefan Eichmüller - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Sylke Gellrich - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Chalid Assaf - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Brigitte Dreno - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Meinhard Schiller - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Olivier Dereure - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Marion Baudard - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Martine Bagot - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Amir Khammari - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Pascal Bleuzen - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Vincent Bataille - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Anna Derbij - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Nicole Wiedemann - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Tim Waterboer - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Monika Lusky - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Bruce Acres - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Mirjana Urosevic-Maiwald - Zurich, Heidelberg, Berlin, Krefeld, Nantes, Munster, Montpellier, Montpellier, Créteil, Illkirch (Strasbourg)
Détails de publication: Molecular therapy, Vol.18(6), pp.1244-1247
Éditeur: Nature Publishing Group
Nombre de pages: 4
Identifiants: 99156956209311
Unité académique: Pathogenesis and Control of Chronic and Emerging Infections - PCCEI
Langue: English
Type de ressource: Journal article